The Evolving Role of Multimodality Imaging in Heart Failure

Chapter
First Online:

Abstract

In patients with LV dysfunction, multimodality imaging offers the opportunity to obtain continued information on regional and global cardiac function, myocardial viability, coronary anatomy and regional relative or absolute myocardial perfusion.

The different modalities may be performed separately and integrated/fused afterwards (i.e. through hybrid imaging) or may be used in a single step approach to define HF etiology, the extent and severity of myocardial damage/ischemia, indicate and predict the response to targeted treatments (i.e. CRT, coronary revascularization) as well as to perform pre-interventional assessment (i.e. to program trans-catheter ablation of arrhythmias or valvular interventions)

Keywords

Myocardial Perfusion Cardiac Magnetic Resonance Cardiac Resynchronisation Therapy Compute Tomography Coronary Angiography Global Longitudinal Strain 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Berman DS. Fourth annual Mario S. Verani, MD memorial lecture: noninvasive imaging in coronary artery disease: changing roles, changing players. J Nucl Cardiol. 2006;13:457–73.CrossRefPubMedGoogle Scholar
  2. 2.
    Gaemperli O, Bengel FM, Kaufmann PA. Cardiac hybrid imaging. Eur Heart J. 2011;32:2100–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Flotats A, Knuuti J, Gutberlet M, Marcassa C, Bengel FM, Kaufmann PA, Rees MR, Hesse B, Cardiovascular Committee of the EANM, the ESCR and the ECNC. Hybrid cardiac imaging: SPECT/CT and PET/CT. A joint position statement by the European Association of Nuclear Medicine (EANM), the European Society of Cardiac Radiology (ESCR) and the European Council of Nuclear Cardiology (ECNC). Eur J Nucl Med Mol Imaging. 2011;38:201–12.CrossRefPubMedGoogle Scholar
  4. 4.
    Javadi MS, Lautamäki R, Merrill J, et al. Definition of vascular territories on myocardial perfusion images by integration with true coronary anatomy: a hybrid PET/CT analysis. J Nucl Med. 2010;51:198–203.CrossRefPubMedGoogle Scholar
  5. 5.
    Liga R, Vontobel J, Rovai D, et al. Multicentre multi-device hybrid imaging study of coronary artery disease: results from the EValuation of INtegrated Cardiac Imaging for the Detection and Characterization of Ischaemic Heart Disease (EVINCI) hybrid imaging population. Eur Heart J Cardiovasc Imaging. 2016;17:951–60. doi: 10.1093/ehjci/jew038.CrossRefPubMedGoogle Scholar
  6. 6.
    Pazhenkottil AP, Nkoulou RN, Ghadri JR, et al. Prognostic value of cardiac hybrid imaging integrating single-photon emission computed tomography with coronary computed tomography angiography. Eur Heart J. 2011;32:1465–71.CrossRefPubMedGoogle Scholar
  7. 7.
    Ghali JK. CABG in patients with left ventricular dysfunction. N Engl J Med. 2011;365:468 .author reply 470–1CrossRefPubMedGoogle Scholar
  8. 8.
    O’Connor CM, Velazquez EJ, Gardner LH, et al. Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy a 25-year experience from the Duke cardiovascular disease databank. Am J Cardiol. 2002;90:101–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Hachamovitch R, Rozanski A, Shaw LJ, et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J. 2011;32:1012–24.CrossRefPubMedGoogle Scholar
  10. 10.
    Farzaneh-Far A, Borges-Neto S. Ischemic burden, treatment allocation, and outcomes in stable coronary artery disease. Circ Cardiovasc Imaging. 2011;4:746–53.CrossRefPubMedGoogle Scholar
  11. 11.
    Shaw LJ, Berman DS, Maron DJ, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117:1283–91.CrossRefPubMedGoogle Scholar
  12. 12.
    Abraham A, Nichol G, Williams KA, et al. 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial. J Nucl Med. 2010;51:567–74.CrossRefPubMedGoogle Scholar
  13. 13.
    Beanlands RS, Ruddy TD, deKemp RA, et al. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol. 2002;40:1735–43.CrossRefPubMedGoogle Scholar
  14. 14.
    Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation. 2007;116:434–48.CrossRefPubMedGoogle Scholar
  15. 15.
    Lionetti V, Guiducci L, Simioniuc A, et al. Mismatch between uniform increase in cardiac glucose uptake and regional contractile dysfunction in pacing-induced heart failure. Am J Physiol Heart Circ Physiol. 2007;293:H2747–56.CrossRefPubMedGoogle Scholar
  16. 16.
    Neglia D, De Caterina A, Marraccini P, et al. Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2007;293:H3270–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Kadkhodayan A, Lin CH, Coggan AR, et al.. Sex affects myocardial blood flow and fatty acid substrate metabolism in humans with nonischemic heart failure. J Nucl Cardiol. 2016. doi:  10.1007/s12350-016-0467-6.
  18. 18.
    Schwaiger M, Hicks R. The clinical role of metabolic imaging of the heart by positron emission tomography. J Nucl Med. 1991;32:565–78.PubMedGoogle Scholar
  19. 19.
    Buxton DB, Schwaiger M, Nguyen A, Phelps ME, Schelbert HR. Radiolabeled acetate as a tracer of myocardial tricarboxylic acid cycle flux. Circ Res. 1988;63:628–34.CrossRefPubMedGoogle Scholar
  20. 20.
    Beanlands RS, Nahmias C, Gordon E, Coates G, deKemp R, Firnau G, Fallen E. The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: a double-blind, placebo-controlled, positron-emission tomography study. Circulation. 2000;102:2070–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Gambhir SS, Schwaiger M, Huang SC, Krivokapich J, Schelbert HR, Nienaber CA, Phelps ME. Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and fluorine-18 deoxyglucose. J Nucl Med. 1989;30:359–66.PubMedGoogle Scholar
  22. 22.
    Morita K, Katoh C, Yoshinaga K, et al. Quantitative analysis of myocardial glucose utilization in patients with left ventricular dysfunction by means of 18F-FDG dynamic positron tomography and three-compartment analysis. Eur J Nucl Med Mol Imaging. 2005;32:806–12.CrossRefPubMedGoogle Scholar
  23. 23.
    Masci PG, Marinelli M, Piacenti M, et al. Myocardial structural, perfusion, and metabolic correlates of left bundle branch block mechanical derangement in patients with dilated cardiomyopathy: a tagged cardiac magnetic resonance and positron emission tomography study. Circ Cardiovasc Imaging. 2010;3:482–90.CrossRefPubMedGoogle Scholar
  24. 24.
    Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, Schelbert H. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med. 1986;314:884–8.CrossRefPubMedGoogle Scholar
  25. 25.
    D’Egidio G, Nichol G, Williams KA, et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. JACC Cardiovasc Imaging. 2009;2:1060–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Lautamäki R, Schuleri KH, Sasano T, et al. Integration of infarct size, tissue perfusion, and metabolism by hybrid cardiac positron emission tomography/computed tomography: evaluation in a porcine model of myocardial infarction. Circ Cardiovasc Imaging. 2009;2:299–305.CrossRefPubMedGoogle Scholar
  27. 27.
    Chareonthaitawee P, Schaefers K, Baker CS, et al. Assessment of infarct size by positron emission tomography and [18F]2-fluoro-2-deoxy-D-glucose: a new absolute threshold technique. Eur J Nucl Med Mol Imaging. 2002;29:203–15.CrossRefPubMedGoogle Scholar
  28. 28.
    Pagano D, Bonser RS, Townend JN, et al. Predictive value of dobutamine echocardiography and positron emission tomography in identifying hibernating myocardium in patients with postischaemic heart failure. Heart. 1998;79:281–8.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Rischpler C, Nekolla SG, Dregely I, Schwaiger M. Hybrid PET/MR imaging of the heart: potential, initial experiences, and future prospects. J Nucl Med. 2013;54:402–15.CrossRefPubMedGoogle Scholar
  30. 30.
    Greenwood JP, Maredia N, Younger JF, et al. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet. 2012;379:453–60.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Vontobel J, Liga R, Possner M, et al. MR-based attenuation correction for cardiac FDG PET on a hybrid PET/MRI scanner: comparison with standard CT attenuation correction. Eur J Nucl Med Mol Imaging. 2015;42:1574–80.CrossRefPubMedGoogle Scholar
  32. 32.
    Ratib O, Nkoulou R, Schwaiger M. Cardiovascular clinical applications of PET/MRI. Clin Transl Imaging. 2013;1:65–71.CrossRefGoogle Scholar
  33. 33.
    Aquaro GD, Frijia F, Positano V, et al. 3D CMR mapping of metabolism by hyperpolarized 13C-pyruvate in ischemia-reperfusion. JACC Cardiovasc Imaging. 2013;6:743–4.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Dodd MS, Atherton HJ, Carr CA, et al. Impaired in vivo mitochondrial Krebs cycle activity after myocardial infarction assessed using hyperpolarized magnetic resonance spectroscopy. Circ Cardiovasc Imaging. 2014;7:895–904.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Bristow MR. The autonomic nervous system in heart failure. N Engl J Med. 1984;311:850–1.CrossRefPubMedGoogle Scholar
  36. 36.
    Hachamovitch R, Nutter B, Menon V, Cerqueira MD. Predicting risk versus predicting potential survival benefit using 123I-mIBG imaging in patients with systolic dysfunction eligible for implantable cardiac defibrillator implantation: analysis of data from the prospective ADMIRE-HF Study. Circ Cardiovasc Imaging. 2015;8(12). pii: e003110. doi:  10.1161/CIRCIMAGING.114.003110, PubMed PMID: 26666380.
  37. 37.
    Gimelli A, Liga R, Giorgetti A, et al. Assessment of myocardial adrenergic innervation with a solid-state dedicated cardiac cadmium-zinc-telluride camera: first clinical experience. Eur Heart J Cardiovasc Imaging. 2014;15:575–85.CrossRefPubMedGoogle Scholar
  38. 38.
    Gimelli A, Liga R, Genovesi D, et al. Association between left ventricular regional sympathetic denervation and mechanical dyssynchrony in phase analysis: a cardiac CZT study. Eur J Nucl Med Mol Imaging. 2014;41:946–55.CrossRefPubMedGoogle Scholar
  39. 39.
    Caldwell JH, Link JM, Levy WC, Poole JE, Stratton JR. Evidence for pre to postsynaptic mismatch of the cardiac sympathetic nervous system in ischemic congestive heart failure. J Nucl Med. 2008;49:234–41.CrossRefPubMedGoogle Scholar
  40. 40.
    Arora R, Ferrick KJ, Nakata T, Kaplan RC, Rozengarten M, Latif F, Ng K, Marcano V, Heller S, Fisher JD, Travin MI. I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol 2003;10:121–31.Google Scholar
  41. 41.
    Duell J, Dilsizian V, Smith M, Chen W, Dickfeld T. Nuclear imaging guidance for ablation of ventricular arrhythmias. Curr Cardiol Rep. 2016;18(2):19. doi: 10.1007/s11886-015-0697-2 .PubMed PMID: 26783000CrossRefPubMedGoogle Scholar
  42. 42.
    McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803–69.CrossRefPubMedGoogle Scholar
  43. 43.
    Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.CrossRefPubMedGoogle Scholar
  44. 44.
    CM Y, Chan YS, Zhang Q, et al. Benefits of cardiac resynchronization therapy for heart failure patients with narrow QRS complexes and coexisting systolic asynchrony by echocardiography. J Am Coll Cardiol. 2006;48:2251–7.CrossRefGoogle Scholar
  45. 45.
    Ruschitzka F, Abraham WT, Singh JP, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013;369:1395–405.CrossRefPubMedGoogle Scholar
  46. 46.
    Fornwalt BK, Sprague WW, Carew JD, et al. Variability in tissue Doppler echocardiographic measures of dyssynchrony is reduced with use of a larger region of interest. J Am Soc Echocardiogr. 2009;22:478–85.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Chung ES, Leon AR, Tavazzi L, et al. Results of the predictors of response to CRT (PROSPECT) trial. Circulation. 2008;117:2608–16.CrossRefPubMedGoogle Scholar
  48. 48.
    Seo Y, Ishizu T, Kawamura R, et al. Three-dimensional propagation imaging of left ventricular activation by speckle-tracking echocardiography to predict responses to cardiac resynchronization therapy. J Am Soc Echocardiogr. 2015;28:606–14.CrossRefPubMedGoogle Scholar
  49. 49.
    Marzullo P, Parodi O, Schelbert HR, L’Abbate A. Regional myocardial dysfunction in patients with angina at rest and response to isosorbide dinitrate assessed by phase analysis of radionuclide ventriculograms. J Am Coll Cardiol. 1984;3:1357–66.CrossRefPubMedGoogle Scholar
  50. 50.
    Boogers MM, Van Kriekinge SD, Henneman MM, et al. Quantitative gated SPECT-derived phase analysis on gated myocardial perfusion SPECT detects left ventricular dyssynchrony and predicts response to cardiac resynchronization therapy. J Nucl Med. 2009;50:718–25.CrossRefPubMedGoogle Scholar
  51. 51.
    Gimelli A, Liga R, Giorgetti A, et al. Determinants of left ventricular mechanical dyssynchrony in patients submitted to myocardial perfusion imaging: a cardiac CZT study. J Nucl Cardiol. 2016;23:728–36.CrossRefPubMedGoogle Scholar
  52. 52.
    Einstein AJ, Blankstein R, Andrews H, et al. Comparison of image quality, myocardial perfusion, and left ventricular function between standard imaging and single-injection ultra-low-dose imaging using a high-efficiency SPECT camera: the MILLISIEVERT study. J Nucl Med. 2014;55:1430–7.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Acampa W, Buechel RR, Gimelli A. Low dose in nuclear cardiology: state of the art in the era of new cadmium-zinc-telluride cameras. Eur Heart J Cardiovasc Imaging. 2016;17:591–5. doi: 10.1093/ehjci/jew036.CrossRefPubMedGoogle Scholar
  54. 54.
    Boogers MJ, Chen J, van Bommel RJ, et al. Optimal left ventricular lead position assessed with phase analysis on gated myocardial perfusion SPECT. Eur J Nucl Med Mol Imaging. 2011;38:230–8.CrossRefPubMedGoogle Scholar
  55. 55.
    Bakos Z, Markstad H, Ostenfeld E, et al. Combined preoperative information using a bullseye plot from speckle tracking echocardiography, cardiac CT scan, and MRI scan: targeted left ventricular lead implantation in patients receiving cardiac resynchronization therapy. Eur Heart J Cardiovasc Imaging. 2014;15:523–31.CrossRefPubMedGoogle Scholar
  56. 56.
    Mavrogeni SI, Markousis-Mavrogenis G, Heutemann D, et al. “How many times must a man look up before he can really see the sky?” Rheumatic cardiovascular disease in the era of multimodality imaging. World J Methodol. 2015;5:136–43.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Pardos-Gea J, Avegliano G, Evangelista A, Vilardell M, Ordi-Ros J. Cardiac manifestations other than valvulopathy in antiphospholipid syndrome: long-time echocardiography follow-up study. Int J Rheum Dis. 2015;18:76–83.CrossRefPubMedGoogle Scholar
  58. 58.
    Mavrogeni S, Sfikakis PP, Gialafos E, et al. Cardiac tissue characterization and the diagnostic value of cardiovascular magnetic resonance in systemic connective tissue diseases. Arthritis Care Res (Hoboken). 2014;66:104–12.CrossRefGoogle Scholar
  59. 59.
    Carabello BA, Paulus WJ. Aortic stenosis. Lancet. 2009;373:956–66.CrossRefPubMedGoogle Scholar
  60. 60.
    Kamperidis V, Delgado V, van Mieghem NM, Kappetein AP, Leon MB, Bax JJ. Diagnosis and management of aortic valve stenosis in patients with heart failure. Eur J Heart Fail. 2016;18:469–81. doi: 10.1002/ejhf.466.CrossRefPubMedGoogle Scholar
  61. 61.
    Cueff C, Serfaty JM, Cimadevilla C, et al. Measurement of aortic valve calcification using multislice computed tomography: correlation with haemodynamic severity of aortic stenosis and clinical implication for patients with low ejection fraction. Heart. 2011;97:721–6.CrossRefPubMedGoogle Scholar
  62. 62.
    Monin JL, Quéré JP, Monchi M, et al. Low-gradient aortic stenosis: operative risk stratification and predictors for long-term outcome: a multicenter study using dobutamine stress hemodynamics. Circulation. 2003;108:319–24.CrossRefPubMedGoogle Scholar
  63. 63.
    Petronio AS, De Carlo M, Bedogni F, et al. Safety and efficacy of the subclavian approach for transcatheter aortic valve implantation with the CoreValve revalving system. Circ Cardiovasc Interv. 2010;3:359–66.CrossRefPubMedGoogle Scholar
  64. 64.
    Mason JW, Bristow MR, Billingham ME, Daniels JR. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects inman: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep. 1978;62:857–64.PubMedGoogle Scholar
  65. 65.
    Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37:1671–80 pii: ehw022.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiography. 2014;27:911–39.CrossRefGoogle Scholar
  67. 67.
    Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132:1570–9.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Fontana M, Banypersad SM, Treibel TA, et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7:157–65.CrossRefPubMedGoogle Scholar
  69. 69.
    Li R, Yang ZG, Wen LY, et al. Regional myocardial microvascular dysfunction in cardiac amyloid light-chain amyloidosis: assessment with 3 T cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2016;18:16.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Hutt DF, Quigley AM, Page J, et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014;15:1289–98.CrossRefPubMedGoogle Scholar
  71. 71.
    Longhi S, Guidalotti PL, Quarta CC, et al. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. JACC Cardiovasc Imaging. 2014;7:531–2.CrossRefPubMedGoogle Scholar
  72. 72.
    Macron L, Lim P, Bensaid A, et al. Single-beat versus multibeat real-time 3D echocardiography for assessing left ventricular volumes and ejection fraction: a comparison study with cardiac magnetic resonance. Circ Cardiovasc Imaging. 2010;3:450–5.CrossRefPubMedGoogle Scholar
  73. 73.
    Toro-Salazar OH, Ferranti J, Lorenzoni R, et al. Feasibility of echocardiographic techniques to detect subclinical cancer therapeutics-related cardiac dysfunction among high-dose patients when compared with cardiac magnetic resonance imaging. J Am Soc Echocardiogr. 2016;29:119–31.CrossRefPubMedGoogle Scholar
  74. 74.
    Giorgetti A, Masci PG, Marras G, et al. Gated SPECT evaluation of left ventricular function using a CZT camera and a fast low-dose clinical protocol: comparison to cardiac magnetic resonance imaging. Eur J Nucl Med Mol Imaging. 2013;40:1869–75.CrossRefPubMedGoogle Scholar
  75. 75.
    Neglia D, Michelassi C, Trivieri MG, et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation. 2002;105:186–93.CrossRefPubMedGoogle Scholar
  76. 76.
    Tio RA, Dabeshlim A, Siebelink HM, et al. Comparison between the prognostic value of left ventricular function and myocardial perfusion reserve in patients with ischemic heart disease. J Nucl Med. 2009;50:214–9.CrossRefPubMedGoogle Scholar
  77. 77.
    Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003;349:1027–35.CrossRefPubMedGoogle Scholar
  78. 78.
    Dorbala S, Vangala D, Bruyere Jr J, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail. 2014;2:358–67.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, Agostini D, Weiland F, Chandna H, Narula J. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55:2212–21.CrossRefPubMedGoogle Scholar
  80. 80.
    Sasano T, Abraham MR, Chang KC, Ashikaga H, Mills KJ, Holt DP, Hilton J, Nekolla SG, Dong J, Lardo AC, Halperin H, Dannals RF, Marban E, Bengel FM. Abnormal sympathetic innervation of viable myocardium and the substrate of ventricular tachycardia after myocardial infarction. J Am Coll Cardiol. 2008;51:2266–75.CrossRefPubMedGoogle Scholar
  81. 81.
    Elkhawad M, Rudd JH. Radiotracer imaging of atherosclerotic plaque biology. Cardiol Clin. 2009;27:345–54.CrossRefPubMedGoogle Scholar
  82. 82.
    Bengel FM. Atherosclerosis imaging on the molecular level. J Nucl Cardiol. 2006;13:111–8.CrossRefPubMedGoogle Scholar
  83. 83.
    Gaemperli O, Liga R, Spyrou N, Rosen SD, Foale R, Kooner JS, Rimoldi OE, Camici PG. Myocardial beta-adrenoceptor down-regulation early after infarction is associated with long-term incidence of congestive heart failure. Eur Heart J. 2010;31:1722–9.CrossRefPubMedGoogle Scholar
  84. 84.
    Kramer CM, Sinusas AJ, Sosnovik DE, French BA, Bengel FM. Multimodality imaging of myocardial injury and remodeling. J Nucl Med. 2010;51(Suppl. 1):107S–21S.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Avril N, Bengel FM. Defining the success of cardiac gene therapy: how can nuclear imaging contribute? Eur J Nucl Med Mol Imaging. 2003;30:757–71.CrossRefPubMedGoogle Scholar
  86. 86.
    Wu JC, Abraham MR, Kraitchman DL. Current perspectives on imaging cardiac stem cell therapy. J Nucl Med. 2010;51(Suppl. 1):128S–36S.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Wagner B, Anton M, Nekolla SG, Reder S, Henke J, Seidl S, Hegenloh R, Miyagawa M, Haubner R, Schwaiger M, Bengel FM. Noninvasive characterization of myocardial molecular interventions by integrated positron emission tomography and computed tomography. J Am Coll Cardiol. 2006;48:2107–15.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Fondazione Toscana Gabriele MonasterioPisaItaly
  2. 2.Cardio-thoracic and Vascular DepartmentUniversity Hospital of PisaPisaItaly

Personalised recommendations